MedTrace Logo

Dexmedetomidine for Reversal of Cocaine's Effects on the Heart

NCT01927640 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2020-01-14

No results posted yet for this study

Summary

This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intranasal cocaine-including vasoconstriction in the coronary microcirculation-both in cocaine-naïve and non-treatment seeking cocaine-addicted subjects.

Conditions

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine (0.3-0.6 mcg/kg) infusion.

DRUG

Normal Saline

Normal saline infusion (10 cc)

DRUG

Intranasal cocaine

Intranasal cocaine (2 mg/kg)

Sponsors & Collaborators

  • Lincy Foundation

    collaborator OTHER

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Ronald G Victor, MD · Cedars-Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-01
Primary Completion
2014-01-15
Completion
2014-01-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01927640 on ClinicalTrials.gov